Last reviewed · How we verify
Avastin, Alimta
Avastin, Alimta is a monoclonal antibody Small molecule drug developed by The Cooper Health System. It is currently in Phase 2 development for Metastatic colorectal cancer, Non-small cell lung cancer, Glioblastoma.
Avastin (bevacizumab) is a monoclonal antibody that targets vascular endothelial growth factor (VEGF), inhibiting angiogenesis and tumor growth.
Avastin (bevacizumab) is a monoclonal antibody that targets vascular endothelial growth factor (VEGF), inhibiting angiogenesis and tumor growth. Used for Metastatic colorectal cancer, Non-small cell lung cancer, Glioblastoma.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Oncology Phase 2 attrition
-2.0pp
Oncology drugs have higher Phase 2-to-Phase 3 attrition than average — many fail to show OS benefit in larger studies.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Avastin, Alimta |
|---|---|
| Sponsor | The Cooper Health System |
| Drug class | monoclonal antibody |
| Target | VEGF |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
By binding to VEGF, Avastin prevents the interaction between VEGF and its receptors on the surface of endothelial cells, thereby blocking the formation of new blood vessels that tumors need to grow and spread.
Approved indications
- Metastatic colorectal cancer
- Non-small cell lung cancer
- Glioblastoma
- Metastatic renal cell carcinoma
- Cervical cancer
- Ovarian, fallopian tube, or primary peritoneal cancer
Common side effects
- Hypertension
- Fatigue
- Proteinuria
- Nasopharyngitis
Key clinical trials
- Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma (PHASE2)
- Pan Tumor Rollover Study (PHASE2)
- SYS6090 Combination Therapy in Advanced Lung Cancer (PHASE1, PHASE2)
- A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene. (PHASE1)
- ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs (PHASE2)
- Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients (PHASE2)
- A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (PHASE2, PHASE3)
- Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Avastin, Alimta CI brief — competitive landscape report
- Avastin, Alimta updates RSS · CI watch RSS
- The Cooper Health System portfolio CI
Frequently asked questions about Avastin, Alimta
What is Avastin, Alimta?
How does Avastin, Alimta work?
What is Avastin, Alimta used for?
Who makes Avastin, Alimta?
What drug class is Avastin, Alimta in?
What development phase is Avastin, Alimta in?
What are the side effects of Avastin, Alimta?
What does Avastin, Alimta target?
Related
- Drug class: All monoclonal antibody drugs
- Target: All drugs targeting VEGF
- Manufacturer: The Cooper Health System — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Metastatic colorectal cancer
- Indication: Drugs for Non-small cell lung cancer
- Indication: Drugs for Glioblastoma
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing